Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q4 EPS of ($0.34), $0.64 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $70.57 million versus the consensus estimate of $18.38 million.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.